Skip to Main Content

James L. Rubenstein

MD PhD

Hematologist-oncologist

Dr. James Rubenstein is a hematologist-oncologist, or a specialist in blood disorders. He has particular expertise in treating patients with neurologic complications from cancer, including patients with non-Hodgkin's lymphoma involving the brain (called central nervous system lymphoma). He also specializes in patients with cancer that has spread to the brain from other parts of the body.

In his research, Rubenstein investigates immunologic tools to improve tumor response to chemotherapy and radiation treatment, and to minimize toxicity from treatment. He is also interested in developing tumor biomarkers to diagnose brain tumors.

Rubenstein earned his medical degree at Weill Cornell Medicine and completed a residency in internal medicine at Stanford Medicine. He earned a doctorate in molecular and cellular neurosciences at the Rockefeller University. He completed a fellowship in hematology and oncology at UCSF, which included training in neuro-oncology.

Rubenstein has won research awards from the Leukemia & Lymphoma Society and the National Cancer Institute. He is a member of the American Society of Hematology, American Society of Clinical Oncology and American Association for Cancer Research.

  • Education

    Cornell University Medical College, 1992

  • Residencies

    Stanford, Internal Medicine, 1995

  • Fellowships

    UCSF Cancer Research Institute, Hematology/Oncology, 1997

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Professor

  • Languages

    French

Where I see patients (1)

    My reviews

    4.9

    Overall Experience
    125 Ratings
    Explained things in a way that was easy to understand
    125 Ratings
    Did the doctor pay attention to your concerns
    123 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    120 Ratings
    Knew the important information about your medical history
    125 Ratings
    The provider showed respect for what you had to say
    124 Ratings
    The provider spent enough time with me
    124 Ratings
    Decorative Caduceus

    Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymph...

    Defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients). The number and severity of all adverse events will be tabulated and...

    Recruiting

    Decorative Caduceus

    Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

    The Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0) will be used to classify and graded any adverse events that occur after the participant has received the hyperpolarized 13C injection.

    Recruiting

    Decorative Caduceus

    Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

    Toxicities will be classified using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The DLT will be based on the tolerability observed during the first cycle. In order for a patient to be assessed for D...

    Recruiting

    Share